• Blood Priming: Blood prim ing of the apheresis machine is at the discretion of the institution. • Apher esis Procedure: The apheresis procedure will be performed in accordance with institutional standards. • PBSC Collection Goal: The PBSC c ollection goal is 2x106 CD34+ cells per Kg at a minimum. Re-MATC H Protocol Page 54 of 106 Version: 20180628 • PBSC Product Testing: Each PBSC collection will be cultured for bacterial and fungal contamination, nucleated cell count and differential, and CD34+ cell enumeration. 15.2.4 GUIDELINES FOR INDUCTION THERAPY AND PBSC COLLECTION As no study drug is administered during the Induction phase of the trial, the Induction regimen for Group A patients and mobilization and collection of PBSCs for stem cell rescue may be administered at UF or other Foundation for t he Accreditation of Cellular Therapy (FACT) -accredited medical institutions under the care of a board- eligible/board -certified pediatric oncologist, with the exception of the first leukapheresis for collection of PBMCs for DC and xALT generation, which mus t occur at the main institution . Subsequent PBSC mobilization and leukapheresis may be conducted according to institutional guidelines. PBSC products collected and cryopreserved at FACT -accredited institutions shall be shipped in a dry shipper to the main institution prior to Consolidation. Dr. Sri Gururangan ( Neuro -Oncology Chair ) will be responsible for providing a roadmap of the induction and salvage chemotherapy regimens to outside oncologists and acquiring documentation of all prescribed medications and any chemotherapy or procedure related toxicities during these periods. Sta ndard medication regimens may need to be adjusted due to hematologic or other toxicities and may be managed at the discretion of the treating pediatric oncologist. Focal boost radiotherapy may be delivered prior to immunotherapy if required for local cont rol. All deviations from intended regimens during induction or salvage therapy will be documented, but not considered a protocol deviation, as is within routine standard of practice for this patient population. All patients must return to the main institution for high -dose Consolidation therapy (Group A) and subsequent immunotherapy. 15.3 Consolidation 15.3.1 PRE-TRANSPLANT EVALUATION • Adequate collection of autologous PBSCs for transplant • Successful production of vaccine • Medical history • Physical examination • Bone Marrow function: - Absolute neutrophil count > 1000/µl (unsupported). - Platelets > 100,000/µl (unsupported).